Antenatal glucocorticoids supplementation and central nervous system development

Curr Drug Metab. 2013 Feb;14(2):160-6.

Abstract

Maternal antenatal therapy with glucocorticoids (GC) is routinely used to prevent lung immaturity. The potential harmful effects on other organs, including in particular the central nervous system (CNS), are still controversial. In the present review we aimed to investigate: i) the beneficial and detrimental effects of antenatal GC treatment in both human and animal models; ii) the potential usefulness of biochemical markers such as calcium binding proteins (S100B, synaptophysin) and cytoskeletal protein of neurons and dendrites (MAP2) in the perinatal period, and iii) whether the assessment of brain markers in different biological fluids could constitute a promising tool for the monitoring of CNS function and/or developmental in fetuses and newborns whose mothers assumed GC antenatally.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Central Nervous System / drug effects*
  • Central Nervous System / embryology
  • Female
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use*
  • Humans
  • Infant, Newborn
  • Maternal-Fetal Exchange*
  • Pregnancy
  • Receptors, Glucocorticoid / metabolism
  • Respiratory Distress Syndrome, Newborn / prevention & control

Substances

  • Glucocorticoids
  • Receptors, Glucocorticoid